Mobocertinib(Exkivity)

Mobocertinib is a prescription drug. It received accelerated approval from the U.S. Food and Drug Administration (FDA) on September 15, 2021, targeting epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Use it strictly as directed by a doctor.

Target

Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation

Dosage and Administration

Route and frequency of administration for Mobocertinib: Oral, once daily.

The dosage of Mobocertinib should be adjusted according to the patient’s actual condition. Please consult a doctor and strictly follow medical advice.

Recommended reading: Dosage and Administration of Mobocertinib

Adverse Reactions

Common adverse reactions: Diarrhea, rash, stomatitis, etc.

Serious adverse reactions: QTc prolongation, ILD/pneumonitis, etc.

Reference article: Adverse Reactions of Mobocertinib

Use in Special Populations

Pregnancy: If you become pregnant or suspect you may be pregnant during treatment, inform your doctor immediately.

Lactation: If you are breastfeeding or planning to breastfeed, inform your doctor. It is not known whether Mobocertinib is excreted in human milk. Do not breastfeed during treatment with Mobocertinib and for 1 week after the last dose.

Precautions for Daily Use

1. Take Mobocertinib strictly as prescribed by your doctor.

2. Mobocertinib may be taken with or without food.

3. Swallow Mobocertinib capsules whole. Do not open, chew, or dissolve the capsule contents.

from FDA，2023.09